IRIS
PERUCCA, EMILIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.374
EU - Europa 5.745
AS - Asia 4.036
AF - Africa 19
SA - Sud America 17
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 9
Totale 18.210
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.314
CN - Cina 3.922
IE - Irlanda 1.765
UA - Ucraina 1.355
DE - Germania 672
FI - Finlandia 574
SE - Svezia 436
GB - Regno Unito 337
IT - Italia 287
FR - Francia 133
RU - Federazione Russa 105
CA - Canada 60
IN - India 43
JP - Giappone 32
BE - Belgio 29
NL - Olanda 19
PL - Polonia 14
MU - Mauritius 13
IL - Israele 10
EU - Europa 9
SG - Singapore 9
AU - Australia 8
BR - Brasile 8
CL - Cile 8
TR - Turchia 4
CZ - Repubblica Ceca 3
EG - Egitto 3
ES - Italia 3
GR - Grecia 3
HK - Hong Kong 3
KR - Corea 3
HU - Ungheria 2
ID - Indonesia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
SI - Slovenia 2
UG - Uganda 2
UZ - Uzbekistan 2
AT - Austria 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
LU - Lussemburgo 1
LV - Lettonia 1
PE - Perù 1
PH - Filippine 1
RO - Romania 1
TH - Thailandia 1
Totale 18.210
Salva come PNG Salva come JPEG
Città #
Chandler 1.861
Dublin 1.765
Jacksonville 1.659
Nanjing 1.222
Ashburn 514
Nanchang 471
Princeton 448
Lawrence 417
Wilmington 412
Shenyang 355
Hebei 347
Changsha 338
Jiaxing 278
Medford 267
Beijing 209
Tianjin 204
Hangzhou 185
Boardman 183
Ann Arbor 175
Helsinki 143
Woodbridge 126
Milan 97
Fairfield 91
Saint Petersburg 85
Shanghai 78
Norwalk 71
Verona 71
Houston 68
Cambridge 51
Toronto 43
Seattle 42
Los Angeles 35
New York 34
Des Moines 31
Brussels 29
Falls Church 27
Kunming 27
Pavia 27
Tokyo 27
Dearborn 23
Pune 22
Jinan 21
San Francisco 21
Taizhou 19
Zhengzhou 19
Piscataway 17
Washington 16
Guangzhou 15
Auburn Hills 14
Ningbo 12
Orange 10
Radomsko 10
Tappahannock 10
Changchun 9
Fuzhou 9
Ottawa 9
Singapore 8
Berlin 7
Chicago 7
Redmond 7
Borås 6
Lanzhou 6
Redwood City 5
Biandronno 4
Como 4
Giv‘atayim 4
Gunzenhausen 4
Jinhua 4
Las Vegas 4
Rockville 4
São Paulo 4
Xian 4
Amsterdam 3
Canberra 3
Chiari 3
Cologno Monzese 3
Dortmund 3
Hefei 3
Jerusalem 3
Kemerovo 3
London 3
Markham 3
Melbourne 3
Palermo 3
Phoenix 3
Takarazuka 3
Valencia 3
Walnut 3
Ashdod 2
Athens 2
Auckland 2
Bengaluru 2
Bergamo 2
Cairo 2
Catania 2
Cleveland 2
Delhi 2
Eindhoven 2
Esslingen am Neckar 2
Frankfurt am Main 2
Totale 12.923
Salva come PNG Salva come JPEG
Nome #
No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia risk—An analysis of Finnish health register and German health insurance data 125
Low risk pragmatic trials do not always require participants' informed consent 110
Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbamazepine in healthy women 96
Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. 82
Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. 82
Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. on behalf of the SOPHIE Study Group. 80
A Prospective study on the effects of antiepileptic drugs on the human foetus: The European Registry initiative 79
A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. 79
Alterazioni del campo visivo in soggetti epilettici in trattamento cronico con vigabatrin. 77
Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. 76
Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: a open, prospective, long-term study 74
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. 74
Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience 73
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine sources of variability and preliminary observations on relations with clinical response. 71
The remarkable story of valproic acid 71
The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction 70
A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma 70
Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and puerperium. 70
What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? 70
A simple and rapid HPLC-UV method for the determination of retigabine in human plasma 70
Overtreatment in epilepsy: adverse consequences and mechanisms. 67
A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. 67
A Double-Blind, Placebo-Controlled Study on the Effect of Vigabatrin on In Vivo Parameters of Hepatic Microsomal Enzyme Induction and on the Kinetics of Steroid Oral Contraceptives in Healthy Female Volunteers 67
Addressing overtreatment in patients with refractory epilepsy at a tertiary referral center in Brasil. 66
Erratum The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: The PuLsE (Open Prospective Randomized Long-term Effectiveness) trial (Epilepsia (2014) 55 (893-900) 66
Valproic acid after five decades of use in epilepsy: Time to reconsider the indications of a time-honoured drug 66
Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. 66
The management of refractory idiopathic epilepsies 65
Pharmacokinetic variability of new antiepileptic drugs at different ages. 65
Increased Apparent Oral Clearance of Valproic Acid during Intake of Combined Contraceptive Steroids in Women with Epilepsy 65
A multiparametric investigation of daytime sleepiness and psychomotor functions in epileptic patients treated with phenobarbital and sodium valproate: a comparative controlled study 65
Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. 65
Improving Epilepsy for Life: editorial comment. 64
Gender issues in antiepileptic drug treatment 64
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). 64
Revisiting phenobarbital for epilepsy. 63
The new antiepileptic drugs: Pharmacological and clinical aspects. 63
Adverse drug interactions in epilepsy 63
Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey. 63
Role of valproate across the ages. Treatment of epilepsy in the elderly 62
Drugs in early clinical development. 62
Overtreatment in epilepsy : How it occurs and how it can be avoided 62
A PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG, 62
Tiagabina: aspetti farmacologici e clonici 61
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. 61
What can we learn from clinical trials of anticonvulsant drugs in epilepsy? 61
NICE guidance on newer drugs for epilepsy in adults 61
Influence of aging on serum phenytoin concentrations: A pharmacokinetic analysis based on therapeutic drug monitoring data. 61
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction 61
Concentrations of L-dopa in plasma and plasma ultrafiltrates. 61
A young woman with recurring seizures. 61
Seizure control and treatment in pregnancy. Observations from the EURAP Epilepsy Pregnancy Registry 61
Farmacocinetica delle benzodiazepine. 61
Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. 61
Recent advances in the diagnosis and treatment of epilepsy 60
Withdrawing antiepileptic drugs in seizure-free patients: what are the cognitive benefits? 60
Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries 60
Antiepileptic drug selection for people with HIV/AIDS: Evidence-based guidelines from the ILAE and AAN 60
Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation 60
Commentary: Epilepsy is a Global Problem 60
Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. 60
Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. 60
Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders 59
Offspring of mothers with epilepsy. 59
Assessing risk to benefit ratio in antiepileptic drug therapy 59
Plasma gabapentin concentrations in children with epilepsy: Influence of age, relationship with dosage, and preliminary observations on correlation with clinical response 59
The International League Against Epilepsy at the threshold of its second century: year 1. 59
Acute tolerance to the tremorolytic effect of primidone. 59
Commentary: Why an International Epilepsy Day? 59
The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: The PuLsE (OpenProspective RandomizedLong-termEffectiveness) trial 59
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. 58
Omeprazole Does Not Enhance the Metabolism of Phenacetin, a Marker of CYP1A2 Activity, in Healthy Volunteers 58
The clinical pharmacokinetics of the newer antiepileptic drugs - Focus on topiramate, zonisamide and tiagabine 58
Epilessia nell'anziano:dati dai registri di un centro neurologico. 58
Trial duration and follow-up 57
Marketed new antiepileptic drugs: are they better than old-generation agents? 57
Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. 57
Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. 57
Combination therapy and drug interactions. 57
When clinical trials make history: Demonstrating efficacy of new antiepileptic drugs as monotherapy. 57
Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma 57
Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation 56
Patient-tailored antiepileptic drug therapy: Predicting response to antiepileptic drugs 56
Anticonvulsants 56
New and forthcoming anti-epileptic drugs. 56
Effects of phenytoin on the in vivo kinetics of thiamine and its phosphoesters in rat nervous tissues 56
Topiramate: from a drug of last resort to a first-line treatment option. 9th Iranian Congress of Neurology and Clinical Neurophysiology 55
Tiagabine in the treatment of epilepsy. A clinical review with a guide for the prescribing physician. 55
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the presence and absence of enzyme induction by carbamazepine. 55
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. 55
Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction. 55
Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects 55
The disposition of theophylline in patients with lung and breast cancer. 55
Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: An in vitro study 55
Clinical pharmacokinetics of fluvoxamine. 55
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry 55
Malformations in the offspring of pregnant women with epilepsy. Presentation of an international registry of antiepileptic drugs and pregnancy (EURAP) 54
Phenobarbital pharmacokinetics in old age: A case-matched evaluation based on therapeutic drug monitoring data. 54
Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. 54
Daytime sleepiness in healthy university students: A multiparametric study 54
Totale 6.381
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.194
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.194
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.794 1.519 1.934 6 270 8 258 13 280 26 337 132 11
2020/20212.400 276 225 79 240 7 323 7 400 78 351 316 98
2021/20221.632 31 5 64 21 20 36 27 101 100 18 275 934
2022/20235.273 641 314 37 471 518 593 0 355 2.110 25 136 73
2023/20241.577 222 281 58 137 170 413 30 107 11 45 60 43
2024/20251 1 0 0 0 0 0 0 0 0 0 0 0
Totale 18.573